



APPENDIX

PENDING CLAIMS

1 3. A system for averting undesirable drug interaction between a drug
2 and concomitant drug(s), both of which are metabolized by the same molecular species of
3 drug-metabolizing enzyme in humans, or between a drug and concomitant drug(s) that is
4 metabolized by the molecular species of drug-metabolizing enzymes that is inhibited by
5 the said drug, which comprises timed-release control of the said drug or control of the site
6 of release of the said drug to the digestive tract.

1 4. A system for averting undesirable drug interaction between a drug
2 and concomitant drug(s), both of which are metabolized by the drug metabolizing enzyme
3 CYP3A4, or between a drug that inhibits CYP3A4 and concomitant drug(s) that is
4 metabolized by CYP3A4, which comprises timed-release control of the said drug or
5 controlling release specifically in the lower digestive tract of the said drug.

1 7. A drug preparation for averting undesirable drug interaction on the
2 *in vivo* kinetics of a drug by concomitant drug(s) that inhibits *in vivo* metabolism of the
3 said drug in humans, which comprises timed-release control of the concomitant drug or
4 control of the site of release of the concomitant drug to the digestive tract.

1 8. A drug preparation for averting undesirable effects on the blood
2 concentration of a drug by concomitant drug(s) that inhibits the *in vivo* metabolism of the
3 said drug by CYP3A4 in humans, which comprises timed release control of the said drug
4 or controlling release specifically in the lower digestive tract of the concomitant drug.

1 9. The drug preparation according to Claim 8, whereby the said drug
2 and the concomitant drug are a combination selected from anfentanyl, fentanyl,
3 sulfentanyl, cocaine, dihydrocodeine, oxycodone, tramadol, erythromycin,
4 clarithromycin, troleandomycin, azithromycin, itraconazole, ketoconazole, dapsone,
5 midazolam, triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine,

6 nitrendipine, amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nldipine,
7 bepridil, diltiazem, verapamil, astemizole, terfenadine, loratidine, cyclosporine,
8 tacrolimus, rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine,
9 imipramine, amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol,
10 pimozide, carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin,
11 fluvastatin, atrovastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine,
12 vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,
13 methylprednisolone, dexamethasone, proguanil, warfarin, finasteride, flutamide,
14 ondansteron, zatsetrone, cisapride, cortisol, zonisamide, desmethyldiazepam, and
15 conivaptan.

1 12. A method for averting undesirable drug-interaction on the *in vivo*
2 kinetics of a drug by concomitant drug that inhibits the *in vivo* metabolism of the said
3 drug by drug-metabolizing enzymes in humans, comprising administering to patients a
4 drug preparation with which timed-release of the concomitant drug or release site of the
5 concomitant drug to the digestive tract is controllable.

1 13. A method for averting undesirable effects on the blood
2 concentration of a drug by concomitant drug that inhibits the *in vivo* metabolism of the
3 said drug by CYP3A4, comprising administering to patients a drug preparation with
4 which timed-release of the concomitant drug or release of the concomitant drug
5 specifically to the lower digestive tract is controllable.

1 14. The method according to Claim 13, whereby the said drug and the
2 concomitant drug are a combination selected from anfentanyl, fentanyl, sulfentanyl,
3 cocaine, dihydrocodeine, oxycodone, tramadol, erythromycin, clarithromycin,
4 troleandomycin, azithromycin, itraconazole, ketoconazole, dapsone, midazolam,
5 triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine, nitrendipine,
6 amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nldipine, bepridil,
7 diltiazem, verapamil, astemizole, terfenadine, loratidine, cyclosporine, tacrolimus,
8 rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine, imipramine,
9 amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol, pimozide,

10 carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin, fluvastatin,
11 atrovastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine, vincristine,
12 indinavir, ritonavir, saquinavir, testosterone, prednisolone, methylprednisolone,
13 dexamethasone, proguanil, warfarin, finasteride, flutamide, ondansteron, zatsetrone,
14 cisapride, cortisol, zonisamide, desmethyl diazepam, and conivaptan.

1 16. A drug preparation for averting undesirable effects on the blood
2 concentration of a drug by concomitant drug(s) that inhibits the *in vivo* metabolism of the
3 said drug by CYP3A4 in humans, which comprises timed release control of the said drug
4 or controlling release specifically in the lower digestive tract of the concomitant drug,
5 whereby:

6 the said drug and the concomitant drug are a combination selected from
7 anfentanyl, fentanyl, sulfentanyl, cocaine, dihydrocodeine, oxycodone, tramadol,
8 erythromycin, clarithromycin, troleandomycin, azithromycin, itraconazole, ketoconazole,
9 dapsone, midazolam, triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine,
10 nitrendipine, amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nldipine,
11 bepridil, diltiazem, verapamil, astemizole, terfenadine, loratadine, cyclosporine,
12 tacrolimus, rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine,
13 imipramine, amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol,
14 pimozide, carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin,
15 fluvastatin, atrovastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine,
16 vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,
17 methylprednisolone, dexamethasone, proguanil, warfarin, finasteride, flutamide,
18 ondansteron, zatsetrone, cisapride, cortisol, zonisamide, desmethyl diazepam, and
19 conivaptan.

1 17. A drug preparation for averting undesirable drug interaction on the
2 *in vivo* kinetics of a drug by concomitant drug(s) that inhibits *in vivo* metabolism of the
3 said drug in humans, which comprises timed-release control of the concomitant drug or
4 control of the site of release of the concomitant drug to the digestive tract whereby:

5 the said drug and the concomitant drug are a combination selected from
6 anfentanyl, fentanyl, sulfentanyl, cocaine, dihydrocodeine, oxycodone, tramadol,
7 erythromycin, clarithromycin, troleandomycin, azithromycin, itraconazole, ketoconazole,
8 dapsone, midazolam, triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine,
9 nitrendipine, amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nldipine,
10 bepridil, diltiazem, verapamil, astemizole, terfenadine, loratadine, cyclosporine,
11 tacrolimus, rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine,
12 imipramine, amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol,
13 pimozide, carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin,
14 fluvastatin, atrovastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine,
15 vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,
16 methylprednisolone, dexamethasone, proguanil, warfarin, finasteride, flutamide,
17 ondansteron, zatsetrone, cisapride, cortisol, zonisamide, desmethyldiazepam, and
18 conivaptan.

1 18. (New) The system for averting undesirable drug interaction of
2 claim 3, wherein said drug and the concomitant drug are both metabolized by the same
3 molecular species of drug-metabolizing enzyme in humans.

1 19. (New) The system for averting undesirable drug interaction of
2 claim 3, wherein the concomitant drug is metabolized by the molecular species of the
3 drug-metabolizing enzymes that is inhibited by the said drug.

1 20. (New) The system for averting undesirable drug interaction of
2 claim 18, wherein said drug and the concomitant drug are both metabolized by CYP3A4.

1 21. (New) The system for averting undesirable drug interaction of
2 claim 19, the concomitant drug is metabolized by CYP3A4 and said drug inhibits
3 CYP3A4.